Genmab A/S
CSE:GMAB
Genmab A/S
Cost of Revenue
Genmab A/S
Cost of Revenue Peer Comparison
Competitive Cost of Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Genmab A/S
CSE:GMAB
|
Cost of Revenue
-kr411m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Zealand Pharma A/S
CSE:ZEAL
|
Cost of Revenue
-kr19.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Ascendis Pharma A/S
NASDAQ:ASND
|
Cost of Revenue
-€47.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
B
|
Bavarian Nordic A/S
CSE:BAVA
|
Cost of Revenue
-kr2.5B
|
CAGR 3-Years
-28%
|
CAGR 5-Years
-57%
|
CAGR 10-Years
-18%
|
Bioporto A/S
CSE:BIOPOR
|
Cost of Revenue
-kr10.8m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-4%
|
|
Saniona AB
STO:SANION
|
Cost of Revenue
-kr52.7m
|
CAGR 3-Years
19%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
See Also
What is Genmab A/S's Cost of Revenue?
Cost of Revenue
-411m
DKK
Based on the financial report for Mar 31, 2024, Genmab A/S's Cost of Revenue amounts to -411m DKK.